Statistical methods used via this technique in centralized monitoring.
Study Health Check provides early identification of issues related to protocol deviations and determines objective measures of site-specific versus study-wide performance.
Study evaluates the use of AI-supported medical coding module.
Similar to a world-class symphony, a curated site start-up model can accentuate its individual components and lead to swift starts for clinical trials.
A look at the issues in Europe affecting ongoing trials including data management, measures being taken by sponsors, and more.
The value of electronic patient-reported outcomes data in this disease setting.
The answers to meeting biosimulation's growing demand for talent may lie in Africa.
Looking at the road ahead to properly utilizing digital technology in clinical trials.
Tufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.
Clinical trials in this area reflect new science, and corresponding challenges in their execution.
As adoption increases, regulatory bodies are becoming more involved in the oversight of artificial intelligence.
Using existing clinical trial data to proactively model patient safety and efficacy outcomes could aid in accelerating development for areas in need of new therapies.
Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Operational and patient burden considerations for self-collection of blood specimens in clinical trials
Thousands of trials have been halted as a consequence of the coronavirus pandemic, slowing the pace of scientific progress dramatically.
Using IROs can offer the opportunity for doctors to incorporate clinical research as a care option in their practices.
How service providers are helping to accelerate drug development.
Laboratory services organization focuses on easing patient and site burden with improved collection device.
The pandemic spurred an urgency to innovate that improved clinical development in ways that should benefit the industry beyond COVID-19.
All stakeholders must play part in increasing implementation.
By taking on tasks such as clinical trial management, logistics, statistics, and data management, contract research organizations have helped expand the capabilities of their sponsor partners and accelerate drug development timelines.
Determining if an EAC is at risk and key actions to mitigate trial impact.
Promising scientific advances are pacing oncology drug development.
It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.